Date: 2016-03-17
Type of information: Collaboration agreement
Compound: state-of the-art precision medicine cloud platform
Company: Huawei (China) WuXi AppTec (China) WuXi NextCODE (China)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 17, 2016, Huawei, a leading global information and communications technology provider, and WuXi AppTec, the global open-access R&D platform, have announced the signing of a strategic framework agreement to support the China Precision Medicine Initiative (China PMI) through the creation of a state-of the-art precision medicine cloud platform. The agreement builds on Huawei’s industry-leading capabilities and reach in cloud infrastructure, and the unrivalled genomics and precision medicine expertise of WuXi NextCODE, the global genomic information and precision medicine subsidiary of WuXi AppTec. Cloud computing is the way genomic big data will be used to drive precision medicine innovation and deliver better healthcare in a cost-efficient manner.WuXi AppTec and Huawei will follow the guidance of the China Food and Drug Administration (CFDA) and work closely with third-party secure life-science cloud providers to develop the data standards and exchange framework required to deliver the China PMI.
Financial terms:
Latest news:
